Recently, the Telpegfilgrastim injection (Chinese trade name: 珮金) of Xiamen Amoytop Biotech Co., Ltd. is approved for marketing by China NMPA. This drug is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

The Telpegfilgrastim injection is a Y-shaped polyethylene glycol (PEG) modified human granulocyte colony-stimulating factor (rhG-CSF), which stimulates bone marrow hematopoietic stem cells to differentiate into granulocytes, promotes the proliferation, maturation, and release of granulocytes, and restores the number of granulocytes in peripheral blood, to decrease the incidence of infection in tumor patients after chemotherapy. The marketing of this drug provides more treatment options for patients.